GlassScriptPhysician profile
Nicole Francesca Velez
NPI 1205095486
$6,286.69
in general payments reported to CMS, 2019-2025
27 companies · $570 in 2025
The $570 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,113 · 2020: $170 · 2021: $562 · 2022: $1,186 · 2023: $1,257 · 2024: $1,430 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,256.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,340.49 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Galderma Laboratories, L.P. | $844.96 | 2020-2025 | Aklief, Epsolay, Twyneo |
| Genzyme Corporation | $759.29 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $403.32 | 2022-2024 | Sotyktu |
| Revance Therapeutics, INC. | $322.64 | 2024-2025 | Daxxify |
| Regeneron Healthcare Solutions, INC. | $292.50 | 2019-2024 | Dupixent |
| Janssen Biotech, INC. | $270.36 | 2019-2025 | Tremfya |
| Journey Medical Corporation | $268.22 | 2019-2024 | |
| Celgene Corporation | $266.49 | 2019 | |
| Merz North America, INC. | $207.23 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $180.75 | 2020-2025 | |
| Biofrontera INC. | $158.48 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Ucb, INC. | $122.21 | 2021 | |
| Arcutis Biotherapeutics, INC. | $113.09 | 2024 | Zoryve |
| Pfizer INC. | $94.79 | 2019-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $90.18 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $89.85 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $83.87 | 2023 | Dupixent |
| Sun Pharmaceutical Industries INC. | $67.60 | 2019-2022 | |
| Leo Pharma INC. | $65.55 | 2019-2023 | Adbry |
| Lilly USA, LLC | $58.17 | 2022-2023 | Taltz |
| Prugen, INC. Pharmaceuticals | $46.64 | 2019 | |
| Allergan, INC. | $43.67 | 2019 | |
| Amgen INC. | $37.44 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $24.94 | 2019-2020 | |
| Incyte Corporation | $18.52 | 2021 | |
| Organogenesis INC. | $15.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Velez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.